Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing a new combination therapy for neuroblastoma that has a high chance of coming back after treatment. This study is for children with high-risk neuroblastoma who have not gotten more than 1 chemotherapy cycle.
Researchers want to find the best schedule for giving a new vaccine to people with neuroblastoma. The people in this study have neuroblastoma that is in remission (no signs of cancer). In addition, their cancers have a strong chance of coming back (high risk). The vaccine is given with a naturally occurring substance called beta-glucan.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (<sup>131</sup>I) in the laboratory to form the radioactive compound <sup>131</sup>I-MIBG. The <sup>131</sup>I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.
Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:
The standard treatment for head and neck cancers includes high-dose radiation therapy and chemotherapy, but it commonly causes side effects. In this study, researchers are assessing a treatment for head and neck cancer that starts with standard high-dose radiation therapy and chemotherapy and then reduces the doses of both treatments. Patients then have surgery to remove lymph nodes and tissue from the neck area.
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.
Researchers want to find the best dose of a new CAR T cell therapy for esophagogastric cancer. Esophagogastric cancer is cancer of the esophagus or stomach. The people in this study have esophagogastric cancer that has metastasized (spread), including to the peritoneum (lining of the belly). In addition, their cancer makes a protein called mesothelin and keeps growing after initial treatment.
The purpose of this study is to find the highest dose of the investigational drug PC14586 that can be given in patients with solid tumors that came back or continue to grow despite prior therapy and contain a mutation in the TP53 gene. The p53 protein produced by this gene normally tells cells when to stop dividing, but when TP53 is altered (mutated), cancer may result.
